Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARQT Arcutis Biotherapeutics	$13.40 -0.2%	$13.89	$7.64 ▼ $17.75	$1.60B	1.76	2.26 million shs	2.02 million shs
INVA Innoviva	$21.80 +0.5%	$18.99	$15.70 ▼ $21.99	$1.37B	0.37	679,520 shs	985,712 shs
OCUL Ocular Therapeutix	$8.75 +0.2%	$7.70	$5.34 ▼ $11.78	$1.39B	1.42	1.45 million shs	1.70 million shs
PHAT Phathom Pharmaceuticals	$10.64	$4.60	$2.21 ▼ $19.71	$742.82M	0.08	1.50 million shs	1.81 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARQT Arcutis Biotherapeutics	0.00%	-6.54%	-4.82%	-18.21%	+55.62%
INVA Innoviva	0.00%	+0.51%	+16.74%	+23.73%	+36.33%
OCUL Ocular Therapeutix	0.00%	-3.22%	+20.91%	+9.95%	+51.83%
PHAT Phathom Pharmaceuticals	0.00%	+19.28%	+160.15%	+119.83%	-6.26%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARQT Arcutis Biotherapeutics	1.8716 of 5 stars	3.4	1.0	0.0	2.1	1.7	0.6
INVA Innoviva	4.0045 of 5 stars	3.5	0.0	4.2	2.0	1.7	1.9
OCUL Ocular Therapeutix	3.7782 of 5 stars	3.4	1.0	4.1	3.0	2.5	0.0
PHAT Phathom Pharmaceuticals	3.9485 of 5 stars	4.5	2.0	0.0	2.6	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARQT Arcutis Biotherapeutics	2.83	Moderate Buy	$18.80	40.30% Upside
INVA Innoviva	3.00	Buy	$55.00	152.29% Upside
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	85.71% Upside
PHAT Phathom Pharmaceuticals	3.00	Buy	$17.50	64.47% Upside

Current Analyst Ratings Breakdown

Latest INVA, ARQT, OCUL, and PHAT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/9/2025	PHAT Phathom Pharmaceuticals	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $17.00
6/9/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/6/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/23/2025	ARQT Arcutis Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
5/2/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $5.00
5/2/2025	PHAT Phathom Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$18.00 ➝ $12.00
5/2/2025	PHAT Phathom Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $20.00
4/21/2025	PHAT Phathom Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
4/17/2025	PHAT Phathom Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$12.00 ➝ $10.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARQT Arcutis Biotherapeutics	$212.82M	7.51	N/A	N/A	$0.94 per share	14.26
INVA Innoviva	$369.84M	3.70	$4.22 per share	5.17	$10.66 per share	2.05
OCUL Ocular Therapeutix	$59.65M	23.37	N/A	N/A	$0.79 per share	11.08
PHAT Phathom Pharmaceuticals	$81.86M	9.07	N/A	N/A	($1.27) per share	-8.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARQT Arcutis Biotherapeutics	-$262.14M	-$1.04	N/A	N/A	N/A	-140.97%	-119.11%	-45.95%	8/13/2025 (Estimated)
INVA Innoviva	$179.72M	-$1.01	31.59	14.06	N/A	18.31%	20.84%	11.38%	7/29/2025 (Estimated)
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)
PHAT Phathom Pharmaceuticals	-$201.59M	-$5.24	N/A	N/A	N/A	-1,292.14%	N/A	-79.57%	8/6/2025 (Estimated)

Latest INVA, ARQT, OCUL, and PHAT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	INVA Innoviva	N/A	$0.25	N/A	-$0.74	N/A	$88.63 million
5/6/2025	Q1 2025	ARQT Arcutis Biotherapeutics	-$0.21	-$0.20	+$0.01	-$0.20	$64.80 million	$65.85 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARQT Arcutis Biotherapeutics	N/A	N/A	N/A	N/A	N/A
INVA Innoviva	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
PHAT Phathom Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARQT Arcutis Biotherapeutics	0.67	2.46	2.38
INVA Innoviva	0.38	1.79	1.64
OCUL Ocular Therapeutix	0.19	13.01	12.94
PHAT Phathom Pharmaceuticals	N/A	5.73	5.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARQT Arcutis Biotherapeutics	N/A
INVA Innoviva	99.12%
OCUL Ocular Therapeutix	59.21%
PHAT Phathom Pharmaceuticals	99.01%

Insider Ownership

Company	Insider Ownership
ARQT Arcutis Biotherapeutics	9.40%
INVA Innoviva	2.25%
OCUL Ocular Therapeutix	2.30%
PHAT Phathom Pharmaceuticals	23.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARQT Arcutis Biotherapeutics	150	119.20 million	105.93 million	Optionable
INVA Innoviva	100	62.78 million	61.54 million	Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable
PHAT Phathom Pharmaceuticals	110	69.81 million	51.90 million	Optionable

INVA, ARQT, OCUL, and PHAT Headlines

Recent News About These Companies

Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.6% - Should You Sell?

June 16 at 2:16 PM | marketbeat.com

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

June 16 at 8:00 AM | globenewswire.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Gap Up - Should You Buy?

June 12, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Trading 6.4% Higher - Should You Buy?

June 11, 2025 | marketbeat.com

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

June 10, 2025 | seekingalpha.com

Craig Hallum Raises Phathom Pharmaceuticals (NASDAQ:PHAT) Price Target to $17.00

June 10, 2025 | americanbankingnews.com

Phathom Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:PHAT)

June 10, 2025 | americanbankingnews.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 9.7% - Here's What Happened

June 9, 2025 | marketbeat.com

Phathom: Share Price Surge On Patent News May Not Stop The Rot For Long

June 9, 2025 | seekingalpha.com

Traders Purchase High Volume of Call Options on Phathom Pharmaceuticals (NASDAQ:PHAT)

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given New $17.00 Price Target at Craig Hallum

June 9, 2025 | marketbeat.com

Wall Street Analysts Believe Phathom Pharmaceuticals (PHAT) Could Rally 107.4%: Here's is How to Trade

June 9, 2025 | zacks.com

Phathom Pharmaceuticals (NASDAQ:PHAT) Given "Buy" Rating at HC Wainwright

June 9, 2025 | marketbeat.com

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032

June 9, 2025 | finanznachrichten.de

Stifel analysts affirm Buy rating for Phathom Pharmaceuticals stock

June 7, 2025 | investing.com

Wellington Management Group LLP Sells 37,388 Shares of Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT)

June 7, 2025 | marketbeat.com

Phathom Pharmaceuticals price target raised to $29 from $23 at Cantor Fitzgerald

June 6, 2025 | msn.com

Phathom Pharmaceuticals shares soar on FDA exclusivity grant

June 6, 2025 | uk.finance.yahoo.com

Phathom surges 125% after FDA grants petition on Voquezna exclusivity

June 6, 2025 | msn.com

Phathom Pharmaceuticals' (PHAT) Buy Rating Reiterated at Needham & Company LLC

June 6, 2025 | marketbeat.com

Phathom Pharmaceuticals price target raised by $6 at Cantor Fitzgerald, here's why

June 6, 2025 | https://thefly.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INVA, ARQT, OCUL, and PHAT Company Descriptions

Arcutis Biotherapeutics NASDAQ:ARQT

$13.40 -0.03 (-0.22%)

Closing price 04:00 PM Eastern

Extended Trading

$13.36 -0.04 (-0.26%)

As of 04:26 PM Eastern

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Innoviva NASDAQ:INVA

$21.80 +0.11 (+0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$21.79 -0.01 (-0.05%)

As of 04:20 PM Eastern

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Ocular Therapeutix NASDAQ:OCUL

$8.75 +0.02 (+0.23%)

Closing price 04:00 PM Eastern

Extended Trading

$8.85 +0.10 (+1.09%)

As of 04:23 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Phathom Pharmaceuticals NASDAQ:PHAT

$10.64 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$10.59 -0.05 (-0.47%)

As of 04:30 PM Eastern

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time